[
    [
        {
            "time": "2020-10-31",
            "original_text": "【华创证券】大参林（603233）2020年三季报点评：省外拓展稳步推进，单三季度业绩超预期",
            "features": {
                "keywords": [
                    "大参林",
                    "三季报",
                    "省外拓展",
                    "业绩超预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【华创证券】大参林（603233）2020年三季报点评：省外拓展稳步推进，单三季度业绩超预期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-10-31",
            "original_text": "【公司点评】大参林 (603233)丨三季报点评：业绩持续高增长，并购发力河南市场",
            "features": {
                "keywords": [
                    "大参林",
                    "三季报",
                    "业绩高增长",
                    "并购",
                    "河南市场"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【公司点评】大参林 (603233)丨三季报点评：业绩持续高增长，并购发力河南市场",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-10-31",
            "original_text": "三季报亮眼：业绩增长超三成，大参林后劲十足",
            "features": {
                "keywords": [
                    "三季报",
                    "业绩增长",
                    "大参林"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "三季报亮眼：业绩增长超三成，大参林后劲十足",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-01",
            "original_text": "医药2021年度策略：不畏浮云遮望眼",
            "features": {
                "keywords": [
                    "医药",
                    "年度策略"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药2021年度策略：不畏浮云遮望眼",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-01-01",
            "original_text": "医药行业2021年投资策略：“双循环”背景下 “创新升级＋进口替代”引领医药大时代",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "双循环",
                    "创新升级",
                    "进口替代"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2021年投资策略：“双循环”背景下 “创新升级＋进口替代”引领医药大时代",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 5,
                "Duration": 9,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]